

AUG 29 2007

Atty Docket No. 015280-315100US

PTO FAX NO.: 571-273-8300

ATTENTION: Examiner Susan Ungar

Group Art Unit 1642

(cc: Examiner Ungar at FAX NO: 571-273-0837

OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER Susan Ungar

CERTIFICATION OF FACSIMILE TRANSMISSION


I hereby certify that the following documents in re Application of Chandrasekharappa *et al.*, Application No. 09/380,337, filed March 6, 2000 for MEN1, THE GENE ASSOCIATED WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 1, MENIN POLYPEPTIDES AND USES THEREOF are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Supplemental Amendment

Number of pages being transmitted, including this page: 8

Dated: August 29, 2007


Malinda C. Dagit

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: 415-576-0200
Fax: 415-576-0300

vi

RECEIVED
CENTRAL FAX CENTER

AUG 29 2007

I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office.
Fax No. 1-571-273-8300 on 29 Aug 2007

TOWNSEND and TOWNSEND and CREW LLP

By: Mahmud Adafat

PATENT
Attorney Docket No.: 015280-315100US
Client Ref. No.: E-094-1997/0-US-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CHANDRASEKHARAPPA et al.

Application No.: 09/380,337

Filed: March 6, 2000

For: MEN1, THE GENE ASSOCIATED
WITH MULTIPLE ENDOCRINE
NEOPLASIA TYPE 1, MENIN
POLYPEPTIDES AND USES THEREOF

Customer No.: 45115

Confirmation No. 2491

Examiner: Ungar, Susan

Technology Center/Art Unit: 1642

SUPPLEMENTAL AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Further to the telephone conversation with the Examiner on August 22, 2007 and
Supplemental to Applicants' response filed June 18, 2007, please enter the following
amendments and remarks.

Amendments to the Claims are reflected in the listing of claims that begins on
page 2 of this paper.

Remarks begin on page 6 of this paper.